国产欧美日韩第一页另类_日本在线观看综合精品_中文字幕欧美激情一区_人妻少妇精品性色AⅤ_久久大精品婷婷伊人_亚洲麻豆午夜福利_久草视频大全_国产女生裸体免费视频在线看_国产AV八日韩AV动漫_欧美高清午夜福利视频

6
Key oncogenic?pathways
10+
Ongoing R&D projects
100+
Global clinical centers
300+
Global patent applications
300+
Employees

In-house R&D

We develop novel drugs based on our in-house Induced Allosteric Molecule Discovery Platform and iADC Platform.?

?

R&D Focus

Our pipeline?revolves around novel molecular targets in validated cancer pathways. We are currently focusing on six major signaling pathways: RAS, RB, MYC, immune checkpoints, tumor?metabolism and P53.

  • P53 pathway
  • RAS?pathway
  • RB pathway
  • MYC pathway
  • I/O pathway
  • Tumor metabolic pathway
?

Synergistic combinational strategy

Combination therapies are the next frontier in cancer treatment. We use in-house synergistic combinational strategies to maximize the value of our projects.

?
?

Strategic Collaborations with MNC

?

We have external licensing deals to expand global market share.

Strategic Collaborations

?

Professional and International Team

?

Over more than 20 years of experience in drug development, our core management team of serial entrepreneurs has developed a deep well of trust and understanding of the industry. In their first venture in 2003, they led the development and commercialization of China’s first targeted anti-cancer drug, icotinib hydrochloride (Conmana?).

With Jacobio, their second venture, they have chosen to look into targets such as SHP2, for which there are no commercialised drugs on the market yet.

Join Us

Cancer patients cannot afford delays in their treatments and neither can we.
Join our fast-growing team, and help us give hope to patients through the latest research and treatments.